



17W

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Philippe G. Nantermet et al.	
Serial No.:	10/573,232	Case No.: 21546YP
US Nat'l Filing Date:	March 23, 2006	
Int'l Appl'n No.	PCT/US2004/032009	
Int'l Filing Date:	29 September 2004	
For:	BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

MAIL STOP PCT  
Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Services as first class mail in an envelope addressed to:  
Commissioner for Patents, P. O. Box 1450,  
Alexandria, VA 22313-1450, on the date appearing  
Below.

MERCK & CO., INC.


By [Signature] Date June 21, 2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0125

Date: June 21, 2006

## STATEMENT BY APPLICANT

(use ~~as~~ many sheets as necessary)

Sheer

1

of

**1**

**Application Number**

10/573,232

**Filing Date**

**March 23, 2006**

**First Named Inventor**

Philippe G. Nantermet

## Group Art Unit

### To Be Assigned

Examiner Name

### To Be Assigned

Attorney Docket Number

21546YP

Examiner  
Initials\*Cite  
No.

U.S. Patent Document

Number

Kind  
Code  
(if known)Name of Patentee or Applicant  
of Cited Document

Date of Publication of  
Cited Document  
MM-DD-YYYY

Examiner  
Initials\*Cite  
No.

Foreign Patent Document

Office

Number

Kind  
Code  
(if known)Name of Patentee or Applicant  
of Cited Document

Date of Publication of  
Cited Document  
MM-DD-YYYY

A

**WO 2005/005374**

PC

**Sunesis Pharmaceuticals, Inc.**

01/20/2005

B

WO 03/106405

PC

**Sunesis Pharmaceuticals, Inc.**

12/24/2003

Examiner  
SignatureDate  
Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005